Published • loading... • Updated
Covalon Technologies is still a buy, this analyst says
Summary by Cantech Letter
1 Articles
1 Articles
Covalon Technologies is still a buy, this analyst says
On Oct. 21, Research Capital analyst Andre Uddin reaffirmed his “Buy” rating and C$3.75 target price on Covalon Technologies (Covalon Technologies Stock Quote, Chart, News, Analysts, Financials TSXV:COV) after the Mississauga-based medical device company announced a one-time cash dividend of C$0.15 per share, representing a 7.2% yield at its current price of C$2.08. The dividend, […] Source
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium